Payment overview · 2025
General Payments
$215.33
11 reported records · 6 companies
Healthcare provider profile · identity verified
Ashley Diva Hunter, MD
Allopathic & Osteopathic Physicians|Family Medicine · HUNTERSVILLE, NC · NPI 1659877371
Verified facts
What the public records show
CMS Open Payments records show Ashley Diva Hunter, MD received $215.33 in general payments during 2025 across 11 reported records.
Novo Nordisk Inc accounted for 37.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 29 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Symbicort by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 174 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $81.16 | 37.7% | 4 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $52.80 | 24.5% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $28.69 | 13.3% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.60 | 10.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $16.24 | 7.5% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $13.84 | 6.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $215.33 | 11 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $59.49 | 3 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $37.91 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $28.69 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.60 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $21.67 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $16.24 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $14.89 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $13.84 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Ozempic ozempic |
2025 | Ozempic | 2024 | 174 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
29 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
174 | 36 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
92 | 19 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 454 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 451 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 366 | 105 |
| Lisinopril | Lisinopril | 343 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 308 | 94 |
| Omeprazole | Omeprazole | 308 | 90 |
| Losartan Potassium | Losartan Potassium | 282 | 86 |
| Metformin Hcl | Metformin Hcl | 269 | 80 |
| Gabapentin | Gabapentin | 186 | 54 |
| Ozempic | Semaglutide | 174 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 160 | 52 |
| Metoprolol Succinate | Metoprolol Succinate | 151 | 46 |
| Zolpidem Tartrate | Zolpidem Tartrate | 149 | 31 |
| Fluticasone Propionate | Fluticasone Propionate | 140 | 58 |
| Mounjaro | Tirzepatide | 134 | 22 |
| Trazodone Hcl | Trazodone Hcl | 134 | 37 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 34 |
| Alprazolam | Alprazolam | 106 | 27 |
| Simvastatin | Simvastatin | 96 | 27 |
| Eliquis | Apixaban | 92 | 19 |
| Carvedilol | Carvedilol | 86 | 26 |
| Escitalopram Oxalate | Escitalopram Oxalate | 85 | 29 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 79 | 26 |
| Pravastatin Sodium | Pravastatin Sodium | 79 | 21 |
| Ezetimibe | Ezetimibe | 78 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 77 | 27 |
| Sertraline Hcl | Sertraline Hcl | 77 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 75 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 72 | 21 |
| Metoprolol Tartrate | Metoprolol Tartrate | 67 | 22 |
| Montelukast Sodium | Montelukast Sodium | 67 | 20 |
| Citalopram Hbr | Citalopram Hydrobromide | 66 | 19 |
| Bupropion Xl | Bupropion Hcl | 59 | 19 |
| Buspirone Hcl | Buspirone Hcl | 59 | 16 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 59 | 16 |
| Fenofibrate | Fenofibrate | 57 | 16 |
| Potassium Chloride | Potassium Chloride | 57 | 18 |
| Atenolol | Atenolol | 56 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Meloxicam | Meloxicam | 54 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 54 | 17 |
| Celecoxib | Celecoxib | 53 | 13 |
| Allopurinol | Allopurinol | 52 | 19 |
| Clonazepam | Clonazepam | 52 | suppressed |
| Furosemide | Furosemide | 46 | 17 |
| Valacyclovir | Valacyclovir Hcl | 46 | 20 |
| Jardiance | Empagliflozin | 45 | 11 |
| Ropinirole Hcl | Ropinirole Hcl | 45 | 12 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 44 | suppressed |
| Lorazepam | Lorazepam | 43 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 42 | suppressed |
| Famotidine | Famotidine | 40 | 14 |
| Valsartan | Valsartan | 40 | 13 |
| Diclofenac Sodium | Diclofenac Sodium | 38 | 14 |
| Metformin Hcl Er | Metformin Hcl | 37 | 12 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 37 | 11 |
| Methocarbamol | Methocarbamol | 34 | 12 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 34 | 21 |
| Amitriptyline Hcl | Amitriptyline Hcl | 33 | suppressed |
| Testosterone Cypionate | Testosterone Cypionate | 32 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 31 | 17 |
| Glipizide | Glipizide | 29 | suppressed |
| Synthroid | Levothyroxine Sodium | 29 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 28 | suppressed |
| Estradiol | Estradiol | 28 | 13 |
| Fluoxetine Hcl | Fluoxetine Hcl | 28 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 28 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 27 | suppressed |
| Fluconazole | Fluconazole | 27 | 17 |
| Benazepril Hcl | Benazepril Hcl | 26 | suppressed |
| Glipizide Er | Glipizide | 26 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 25 | suppressed |
| Ibuprofen | Ibuprofen | 25 | 12 |
| Meclizine Hcl | Meclizine Hcl | 25 | 15 |
| Mupirocin | Mupirocin | 25 | 11 |
| Donepezil Hcl | Donepezil Hcl | 24 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 24 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 24 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 23 | suppressed |
| Ondansetron Odt | Ondansetron | 23 | 11 |
| Xarelto | Rivaroxaban | 23 | suppressed |
| Primidone | Primidone | 22 | suppressed |
| Spironolactone | Spironolactone | 22 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 21 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 20 | suppressed |
| Mirtazapine | Mirtazapine | 19 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 19 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 19 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 18 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 15 |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 11 |
| Sucralfate | Sucralfate | 17 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 17 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 16 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 16 | suppressed |
| Temazepam | Temazepam | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Glimepiride | Glimepiride | 15 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Trulicity | Dulaglutide | 15 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 15 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 15 | suppressed |
| Baclofen | Baclofen | 14 | suppressed |
| Diazepam | Diazepam | 14 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 14 | suppressed |
| Pregabalin | Pregabalin | 14 | suppressed |
| Clonidine | Clonidine | 13 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 12 | suppressed |
| Rybelsus | Semaglutide | 12 | suppressed |
| Unithroid | Levothyroxine Sodium | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Naproxen | Naproxen | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
| Telmisartan | Telmisartan | 11 | suppressed |
| Vascepa | Icosapent Ethyl | 11 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $215.33 · 11 records | Novo Nordisk Inc | BREZTRI, FREESTYLE LIBRE 3, NURTEC ODT, OTEZLA, Ozempic, REPATHA, UBRELVY, VRAYLAR, Wegovy | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Ozempic play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error